Differences in the clinical significance of CA125 for detecting progression among histological subtypes of epithelial ovarian carcinoma

Kato,Kento; Miyamoto,Morikazu; Nishimura,Soko; Tanabe,Risa; Ito,Tsubasa; Kishimoto,Naohisa; Suminokura,Jin; Otsuka,Yuka; Hada,Taira; Soyama,Hiroaki; Omatsu,Kohei; Hamada,Yoshinobu; Takano,Masashi

doi:10.3892/mco.2026.2950

June-2026 Volume 24 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

June-2026 Volume 24 Issue 6

Full Size Image

Article Open Access

Differences in the clinical significance of CA125 for detecting progression among histological subtypes of epithelial ovarian carcinoma

Authors:
- Kento Kato
- Morikazu Miyamoto
- Soko Nishimura
- Risa Tanabe
- Tsubasa Ito
- Naohisa Kishimoto
- Jin Suminokura
- Yuka Otsuka
- Taira Hada
- Hiroaki Soyama
- Kohei Omatsu
- Yoshinobu Hamada
- Masashi Takano
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama 359‑8513, Japan

Copyright: © Kato et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 41
|
Published online on: April 16, 2026

https://doi.org/10.3892/mco.2026.2950
Expand metrics +

Abstract

Serum cancer antigen 125 (CA125) is the standard tool for surveillance of patients with epithelial ovarian carcinoma (OC). However, its utility may vary by histological subtype. The present study included patients with epithelial OC who completed primary therapy (surgery and chemotherapy) at the National Defense Medical College Hospital (Tokorozawa, Japan) between January 2006 and December 2022, achieved complete or partial response, and had a post‑treatment CA125 level of <35 U/ml. Recurrence was defined using the Response Evaluation Criteria in Solid Tumors criteria via computed tomography (CT) imaging. Surveillance included quarterly CA125 testing for 5 years, and semiannual CT in year 1 followed by annual CT. All patients were classified into Group A, which included clear cell carcinoma and mucinous carcinoma, or Group B, which included high‑grade serous carcinoma and other subtypes. Among 243 patients, there were 85 in Group A and 158 in Group B. First, the diagnostic performance of the standard CA125 cutoff (≥35 U/ml) for detecting recurrence was evaluated. The sensitivity was 28.6% in Group A and 81.8% in Group B; and the specificity was 98.4% in Group A and 98.8% in Group B. Second, because the sensitivity in Group A was very low, the CA125 ratio and a combined model (defined as CA125 ≥35 U/ml or CA125 ratio ≥1.5) were introduced. The CA125 ratio was defined as the maximum CA125 value measured at CT surveillance divided by the CA125 value measured just after the initial treatment for patients with CA125 <35 U/ml. The sensitivity was 66.7% in Group A and 93.5% in Group B; and the specificity was 84.1% in Group A and 86.4% in Group B. In conclusion, the utility of CA125 for the detection of recurrence differs substantially between histological subtypes, highlighting the need for histological subtype‑specific surveillance strategies in epithelial OC.

View Figures

View References

1	Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.PubMed/NCBI View Article : Google Scholar
2	Kuroki L and Guntupalli SR: Treatment of epithelial ovarian cancer. BMJ. 371(m3773)2020.PubMed/NCBI View Article : Google Scholar
3	González-Martín A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, Ray-Coquard I, Tan DSP, Bellet E, Oaknin A, et al: Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 34:833–848. 2023.PubMed/NCBI View Article : Google Scholar
4	NCCN Guidelines: Version 4.2026: Epithelial Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.
5	Liu H, Xu Y, Ji J, Dong R, Qiu H and Dai X: Prognosis of ovarian clear cell cancer compared with other epithelial cancer types: A population-based analysis. Oncol Lett. 19:1947–1957. 2020.PubMed/NCBI View Article : Google Scholar
6	Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA and Akbari MR: CA125 and ovarian cancer: A comprehensive review. Cancers (Basel). 12(3730)2020.PubMed/NCBI View Article : Google Scholar
7	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.PubMed/NCBI View Article : Google Scholar
8	Prat J: FIGO Committee on Gynecologic Oncology. FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: Abridged republication. J Gynecol Oncol. 26:87–89. 2017.PubMed/NCBI View Article : Google Scholar
9	World Health Organization Classification of Tumours Editorial Board, Female Genital Tumours: WHO Classification of Tumours. Vol 4, 5th edition. International Agency for Research on Cancer, Lyon, 2020.
10	Kim SI, Lim MC, Lim J, Won YJ, Seo SS, Kang S and Park SY: Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012. J Gynecol Oncol. 27(e5)2016.PubMed/NCBI View Article : Google Scholar
11	Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, Takano M, Takano T, Susumu N, Aoki D, et al: Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer. 24 (9 Suppl 3):S20–S25. 2014.PubMed/NCBI View Article : Google Scholar
12	Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, et al: An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 147:243–249. 2017.PubMed/NCBI View Article : Google Scholar
13	Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, et al: Clear cell carcinoma of the ovary: A retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer. 94:1369–1374. 2006.PubMed/NCBI View Article : Google Scholar
14	Borella F, Mitidieri M, Cosma S, Benedetto C, Bertero L, Fucina S, Ray-Coquard I, Carapezzi A and Ferraioli D: Update on prognostic and predictive markers in mucinous ovarian cancer. Cancers (Basel). 15(1172)2023.PubMed/NCBI View Article : Google Scholar
15	Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, et al: Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): A randomised trial. Lancet. 376:1155–1163. 2010.PubMed/NCBI View Article : Google Scholar
16	Rustin GJ, Nelstrop AE, Tuxen MK and Lambert HE: Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group Study. Ann Oncol. 7:361–364. 1996.PubMed/NCBI View Article : Google Scholar
17	Gupta D and Lis CG: Role of CA125 in predicting ovarian cancer survival-a review of the epidemiological literature. J Ovarian Res. 2(13)2009.PubMed/NCBI View Article : Google Scholar
18	Plotti F, Guzzo F, Schirò T, Terranova C, De Cicco Nardone C, Montera R, Luvero D, Scaletta G, Lopez S, Capriglione S, et al: Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients. Int J Gynecol Cancer. 29:768–771. 2019.PubMed/NCBI View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Differences in the clinical significance of CA125 for detecting progression among histological subtypes of epithelial ovarian carcinoma

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles